Aktiesnakken — December 2019
-
euters
@Reuters
·
1 t
What deeper OPEC+ oil output cuts mean for the market https://reut.rs/33UJTJ7 -
Bloomberg
@business
·
1 t
The latest U.S. jobs numbers should calm any fears of an impending recession, and with it another yield-curve inversion https://bloom.bg/38dtxhZ via @bopinion -
euters
@Reuters
·
1 t
German industrial orders fell unexpectedly in October as demand at home and from outside the euro zone weakened https://reut.rs/2sRJgmL -
God morgen.
-
Kommentarer til jobtallene: https://www.proinvestor.com/chathistory/58/chat nyheder
-
Hej Mads, det kan jeg ikke. Kan ikke finde de danske pt.
-
The Economist
@TheEconomist
·Japan's growth is once again sagging towards zero. Is Abenomics radical enough?https://www.economist.com/finance-and-economics/2019/12/05/japans-economic-troubles-offer-a-glimpse-of-a-sobering-future?fsrc=scn/tw/te/bl/ed/freeexchangejapanseconomictroublesofferaglimpseofasoberingfuturefinanceandeconomics -
zerohedge @zerohedge
November Heavy Duty Truck Orders Resume Collapse, Down 39% To Weakest Since 2015 https://www.zerohedge.com/economics/november-heavy-duty-truck-orders-resume-collapse-down-39-weakest-2015 … -
Finance News @ftfinancenews
Hedge funds lag stocks and bonds again https://on.ft.com/38djYzv -
Special edition podcast on Saxo's Outrageous Predictions for 2020 - especially the thinking behind this year's theme:
https://soundcloud.com/user-216073084/outrageous-predictions-for-2020 -
Bloomberg
@business
·Negative yields, shrinking unicorns and more challenges for 2020https://www.bloomberg.com/news/articles/2019-12-07/negative-yields-shrinking-unicorns-and-more-challenges-for-2020?utm_campaign=socialflow-organic&cmpid=socialflow-twitter-business&utm_source=twitter&utm_content=business&utm_medium=social -
Reuters
@Reuters
·
11 min
Wall Street Week Ahead: Tariff deadline keeps focus on trade as 2019 draws to close https://reut.rs/350EJwj -
Vil anbefale at man ser denne video i sin fulde længde. Positivt at høre at de ikke regner med mere konkurrence end dem der allerede er annonceret. Lucentis og Eylea omsætter for ca. 100 mia svenske kroner årligt tilsammen og kun ca. 2 ud af 18 mio mennesker bliver behandlet grundet blandt andet høj behandlingspris. Her kan Xbrane komme i spil grundet deres patenterede teknologi som gør det omkostningseffektivt så de kan sænke prisen og stadig tjene gode penge: https://youtu.be/tFaSr6KHr9U
-
God morgen.
-
FDA approves atezolizumab with nab-paclitaxel and carboplatin for metastatic NSCLC without EGFR/ALK aberrationshttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-nab-paclitaxel-and-carboplatin-metastatic-nsclc-without-egfralk
-
Economic Report
‘That’s a lot of jobs!’ economists exclaim after strong payrolls report
By Robert Schroeder https://www.marketwatch.com/discover?url=https%3A%2F%2Fwww.marketwatch.com%2Famp%2Fstory%2Fguid%2Fedb73090-182c-11ea-80d3-a8cb48851594&link=sfmw_tw#https://www.marketwatch.com/amp/story/guid/edb73090-182c-11ea-80d3-a8cb48851594?mod=dist_amp_socialhttps://www.marketwatch.com/discover?url=https%3A%2F%2Fwww.marketwatch.com%2Famp%2Fstory%2Fguid%2Fedb73090-182c-11ea-80d3-a8cb48851594&link=sfmw
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind